Given the association between low-grade systemic inflammation and the development of type 2 diabetes an important yet unanswered question is if DPP-4 secreted by adipocytes is pro-or anti-inflammatory? As a caveat, however, it should be noted that our results were obtained with 3T3-L1 adipocytes in vitro and might not reflect the more complex in vivo situation.
Conclusive analysis of the physiological role of DPP-4 production by adipocytes, especially with a focus on its established interaction with cytokines and chemokines, appears desirable to ensure save therapeutic use of DPP-4 inhibitors in the treatment of hyperglycaemia and type 2 diabetes.
